Fasenra vs Advair Diskus
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Fasenra | US Advair Diskus | |
|---|---|---|
| Generic name | benralizumab | fluticasone/salmeterol |
| Drug class | IL-5 Receptor Antagonist (Biologic) | Inhaled Corticosteroid / LABA Combination |
| Treats | Severe eosinophilic asthma | Asthma and COPD |
| Category | Respiratory | Respiratory |
| Manufacturer | AstraZeneca | GSK |
| Year approved | 2017 | 2000 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $80M | — |
| Common side effects | Headache, Sore throat, Allergic reactions, Injection site reactions | Thrush (mouth infection), Hoarse voice, Headache, Throat irritation |
Advair Diskus
Frequently asked questions
Is Fasenra or Advair Diskus better?
Neither is universally "better." Fasenra (benralizumab) and Advair Diskus (fluticasone/salmeterol) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Fasenra and Advair Diskus?
Fasenra is a IL-5 Receptor Antagonist (Biologic) made by AstraZeneca, while Advair Diskus is a Inhaled Corticosteroid / LABA Combination made by GSK. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Fasenra has the larger estimated TV advertising budget of the two.